Publications

Interim decisions and invitation for comment. Closing date: 12 January 2026.

Interim decisions and invitation for comment. Closing date: 23 January 2026.

Communique from the 11th meeting of the Women's Health Products Working Group, 30 October 2025

We conduct an annual stakeholder survey to improve the way we work with our stakeholders and help report on our key performance indicators.

The report includes data and feedback from the general public (consumers), people and organisations with a TGA business services account (opt-in stakeholders), and state and territory government representatives.

Advisory Committee on Complementary Medicines meeting statement for 31 July 2025

This web publication constitutes a notice for the purposes of regulation 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).

Advisory Committee on Vaccines meeting statement 54

Communique from the 10th meeting of the WHPWG, 17 July 2025

Find out about the AIVC Recommendations for the Composition of Influenza Vaccines for Australia in 2026.

Publication of the decisions made by a delegate of the Secretary

Communique from the 3rd meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 13 August 2025

Advisory Committee on Complementary Medicines meeting statement for 6 March 2025

This study by the TGA assesses the particle filtration efficiency of respirators listed in the ARTG or submitted for compliance testing during the COVID-19 pandemic.

The 86th meeting of the Advisory Committee on Medical Devices (ACMD) was held on 14 August 2025.

Face masks that are intended by their manufacturer to prevent the transmission of diseases between people or are intended to be used in a healthcare environment, are medical devices

Advisory Committee on Vaccines meeting statement 53

This report summarises the extensive batch release testing activities undertaken by the TGA Laboratories for COVID-19 mRNA vaccines.

This survey focused on single-ingredient vitamin D3 products with high sales volumes in Australia between January and December 2023. The TGA tested 13 of the top-selling products, which were supplied by nine different sponsors.

The Australian Sunscreen Exposure Model performs sunscreen exposure calculations that reflect the unique conditions and practices in Australia.

Communique from the 9th meeting of the WHPWG 27 March 2025

Read our business plan 2025-26 to find out about our strategic priorities and activities.

Documents released under the FOI Act in the 2024/25 financial year

The 85th meeting of the Advisory Committee on Medical Devices (ACMD) was held on 12 June 2025.

Based on the data considered in this safety review, we recommend regulatory controls for homosalate and oxybenzone to restrict their permitted concentrations and use in therapeutic sunscreens.

This updated safety review uses the Australian Sunscreen Exposure Model to assess the risk of benzophenone as a degradant in sunscreens.